Relevant BNF section: 5.5
In 1999, Drug and Therapeutics Bulletin (DTB) and the National Institute for Clinical Excellence (NICE) concluded independently that ▼zanamivir (Relenza) should not be used in managing patients with influenza.1,2 Recently, after reviewing further evidence, NICE revised its position regarding use of zanamivir in 'at-risk' adults: it now recommends that, under specific circumstances, the drug should be prescribed for patients at risk who are able to start treatment within 48 hours of the onset of influenza-like symptoms.3 We disagree with this revised advice4 for reasons we explain here.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.